S7 Ep35: FDA Approval Insights: Durvalumab Plus Gemcitabine and Cisplatin in Biliary Tract Cancer
Oct 3, 2022
08:43
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Dr Oh discusses the FDA approval of durvalumab plus gemcitabine and cisplatin in biliary tract cancer, the tolerability of the regimen, and the importance of using immunotherapy to treat this disease.
OncLive® On Air